Cellectis S.A. | Ownership
Companies that own Cellectis S.A.
Baillie Gifford & Co.
631,019
1.5%
22,560
0.01%
04/30/2018
BlackRock Fund Advisors
308,230
0.73%
220
0%
09/06/2018
Norges Bank Investment Management
279,000
0.66%
-43,000
0%
12/31/2017
Bessemer Investment Management LLC
252,897
0.6%
123,700
0.02%
04/30/2018
Arrowstreet Capital LP
142,708
0.34%
142,708
0.01%
06/30/2017
ACATIS Investment Kapitalverwaltungsgesellschaft mbH
120,274
0.28%
2,324
0.09%
06/29/2018
BlackRock Advisors (UK) Ltd.
65,863
0.16%
0
0%
09/06/2018
Credit Suisse Gestión SGIIC SA
48,800
0.12%
3,000
0.09%
03/31/2018
La Banque Postale Asset Management SA
45,677
0.11%
0
0.01%
06/29/2018
CAPFI DELEN Asset Management SA
37,000
0.09%
37,000
0.01%
06/29/2018
| Address |
8, rue de la Croix Jarry
Paris Ile-de-France 75013
France
|
|
Employees
|
- |
| Website |
http://www.cellectis.com |
| Updated |
07/08/2019 |
| Cellectis SA is a biopharmaceutical company, which engages in the research and development of genome engineering technology. The company operates through the following business segments: Therapeutics and Plants. The Therapeutics segment is focused on the development of products in the field of immune-oncology and of novel products outside immuno-oncology to treat other human diseases. |
